OPTN/SRTR 2019 Annual Data Report: Lung
OPTN/SRTR 2019 Annual Data Report: Lung
复制标题
DOI：
10.1111/ajt.16495
复制
发表时间：
2021-02-01
影响因子：
8.8
通讯作者：
Kasiske, B. L.
中科院分区：
文献类型：
--
作者：
Valapour, M.;Lehr, C. J.;Kasiske, B. L.
肺移植的数量每年继续增加，并在2019年达到历史最高水平，等待名单死亡率下降。出现这些趋势的原因是，每年列入移植名单的候选人人数不断增加，捐赠者人数也在不断增加。尽管有这些有利的趋势，但在2019年，6.4%的移植肺没有被移植，优化这些可用器官的使用策略可能会进一步减少等待名单的数量。移植时间继续减少，2019年超过50%的候选人等待3个月或更短时间，尽管政策变化旨在改善分配公平性，但区域异质性仍然存在。移植后生存率继续小幅提高，1年生存率为88.8%; 3年为74.4%; 5年为59.2%; 10年为33.1%。
The number of lung transplants performed continues to increase annually and reached an all-time high in 2019, with decreasing waitlist mortality. These trends are attributable to an increasing number of candidates listed for transplant each year and a continuing increase in the number of donors. Despite these favorable trends, 6.4% of lungs recovered for transplant were not transplanted in 2019, and strategies to optimize use of these available organs may reduce the number of waitlist even further. Time to transplant continued to decrease, as over 50% of candidates waited 3 months or less in 2019, yet regional heterogeneity remained despite policy changes intended to improve allocation equity. Small gains continued in posttransplant survival, with 1-year survival at 88.8%; 3 year, 74.4%; 5 year, 59.2%, and 10 year, 33.1 %.